Literature DB >> 26243625

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Erika Watanabe1, Takuro Nishikawa2, Kazuro Ikawa3, Hiroki Yamaguchi4, Takanari Abematsu5, Shunsuke Nakagawa5, Koichiro Kurauchi5, Yuichi Kodama5, Takayuki Tanabe5, Yuichi Shinkoda6, Kazuaki Matsumoto1, Yasuhiro Okamoto5, Yasuo Takeda1, Yoshifumi Kawano5.   

Abstract

Optimizing systemic busulfan exposure, the area under the concentration-time curve (AUC), improves the outcomes for hematopoietic stem cell transplantation (HSCT). The AUC is conventionally calculated using six plasma concentrations (AUC(0-∞)) drawn after the first of 16 intravenous busulfan doses given as a 2-h infusion every 6 h. The aim of the present study was to develop limited sampling strategies using three or fewer busulfan concentrations to reliably calculate AUC(0-∞) in patients undergoing HSCT. We investigated the pharmacokinetics of busulfan 46 times in 29 pediatric patients receiving intravenous busulfan. Limited sampling strategies using one, two, or three plasma busulfan concentrations were developed by multiple linear regression that showed excellent agreement with AUC(0-∞). In single-point sampling strategies, the AUC(0-∞) predicted based on C(6) (trough level: busulfan plasma concentration 6 h after the start of the infusion) was significantly correlated with, and not statistically different from, actual values as follows: AUC(0-∞) = 2556.5 C6 + 320.9 (r(2) = 0.929, P < 0.0001, mean bias 0.282 %, precision 7.91 %). In contrast, the predicted AUCs derived from the other sampling single points did not meet the criteria. The trough level well correlated with actual AUC(0-∞), suggesting that this time-point is acceptable for busulfan monitoring.

Entities:  

Keywords:  Busulfan; Children; Hematopoietic stem cell transplantation; Limited sampling strategy; Pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 26243625     DOI: 10.1007/s12185-015-1853-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  Molecular basis of ethnic differences in drug disposition and response.

Authors:  H G Xie; R B Kim; A J Wood; C M Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  Measurement of busulfan in plasma by high-performance liquid chromatography.

Authors:  W D Henner; E A Furlong; M D Flaherty; T C Shea; W P Peters
Journal:  J Chromatogr       Date:  1987-05-15

3.  Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children.

Authors:  Yasuhiro Okamoto; Yoshihisa Nagatoshi; Yoshiyuki Kosaka; Akira Kikuchi; Shunichi Kato; Hisato Kigasawa; Yasuo Horikoshi; Megumi Oda; Makoto Kaneda; Tetsuya Mori; Hideo Mugishima; Masahiro Tsuchida; Shuichi Taniguchi; Yoshifumi Kawano
Journal:  Pediatr Transplant       Date:  2014-02-08

4.  Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.

Authors:  L Nguyen; F Leger; S Lennon; C Puozzo
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

5.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.

Authors:  Gérard Michel; Dominique Valteau-Couanet; Jean-Claude Gentet; Hélène Esperou; Gérard Socié; Françoise Méchinaud; François Doz; Bénédicte Neven; Yves Bertrand; Claire Galambrun; François Demeocq; Karima Yakouben; Pierre Bordigoni; Didier Frappaz; Laurent Nguyen; Gilles Vassal
Journal:  Pediatr Blood Cancer       Date:  2011-01-19       Impact factor: 3.167

7.  Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation.

Authors:  Yasushi Takamatsu; Noriaki Sasaki; Tetsuya Eto; Koji Nagafuji; Yasunobu Abe; Ilseung Choi; Kentaro Ogata; Shuuji Hara; Junji Suzumiya; Kazuo Tamura
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  Association of busulfan area under the curve with veno-occlusive disease following BMT.

Authors:  S P Dix; J R Wingard; R E Mullins; I Jerkunica; T G Davidson; C E Gilmore; R C York; L S Lin; S M Devine; R B Geller; L T Heffner; C D Hillyer; H K Holland; E F Winton; R Saral
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

Review 9.  Therapeutic drug monitoring of busulfan in transplantation.

Authors:  J A Russell; S B Kangarloo
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.

Authors:  L Nguyen; D Fuller; S Lennon; F Leger; C Puozzo
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

View more
  3 in total

1.  HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.

Authors:  Masatoshi Takagi; Yasuyoshi Ishiwata; Yuki Aoki; Satoshi Miyamoto; Akihiro Hoshino; Kazuaki Matsumoto; Akira Nishimura; Mari Tanaka; Masakatsu Yanagimachi; Noriko Mitsuiki; Kohsuke Imai; Hirokazu Kanegane; Michiko Kajiwara; Kanako Takikawa; Tsukasa Mae; Osamu Tomita; Junya Fujimura; Masato Yasuhara; Daisuke Tomizawa; Shuki Mizutani; Tomohiro Morio
Journal:  Int J Hematol       Date:  2017-02-09       Impact factor: 2.490

2.  Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?

Authors:  Abdullah Alsultan; Ahmed A Albassam; Abdullah Alturki; Abdulrahman Alsultan; Mohammed Essa; Bader Almuzzaini; Salman Alfadhel
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

3.  Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts.

Authors:  Chuwen Huang; Yuhua Qu; Sha Liu; Shushan Nie; Hua Jiang
Journal:  Transl Pediatr       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.